CORD-19:68a7101a90454172c91785d8c352f776a82df5d4 / 914242-914584 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T71014","span":{"begin":0,"end":342},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"To identify markers for early disease, autoantibody profiling was performed with a phage display technique, called serological antigen selection (SAS), on pooled CSF from Clinically Isolated Syndrome (CIS) patients (n = 4), who developed definite MS, early Relapsing Remitting (RR) MS (n = 6) and Primary Progressive (PP) MS (n = 6) patients."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T188","span":{"begin":0,"end":342},"obj":"Sentence"}],"text":"To identify markers for early disease, autoantibody profiling was performed with a phage display technique, called serological antigen selection (SAS), on pooled CSF from Clinically Isolated Syndrome (CIS) patients (n = 4), who developed definite MS, early Relapsing Remitting (RR) MS (n = 6) and Primary Progressive (PP) MS (n = 6) patients."}

{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T3809","span":{"begin":162,"end":165},"obj":"Body_part"},{"id":"T3810","span":{"begin":247,"end":249},"obj":"Body_part"},{"id":"T3811","span":{"begin":282,"end":284},"obj":"Body_part"},{"id":"T3812","span":{"begin":322,"end":324},"obj":"Body_part"}],"attributes":[{"id":"A3809","pred":"uberon_id","subj":"T3809","obj":"http://purl.obolibrary.org/obo/UBERON_0001359"},{"id":"A3810","pred":"uberon_id","subj":"T3810","obj":"http://purl.obolibrary.org/obo/UBERON_0001877"},{"id":"A3811","pred":"uberon_id","subj":"T3811","obj":"http://purl.obolibrary.org/obo/UBERON_0001877"},{"id":"A3812","pred":"uberon_id","subj":"T3812","obj":"http://purl.obolibrary.org/obo/UBERON_0001877"}],"text":"To identify markers for early disease, autoantibody profiling was performed with a phage display technique, called serological antigen selection (SAS), on pooled CSF from Clinically Isolated Syndrome (CIS) patients (n = 4), who developed definite MS, early Relapsing Remitting (RR) MS (n = 6) and Primary Progressive (PP) MS (n = 6) patients."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T5724","span":{"begin":201,"end":204},"obj":"Disease"},{"id":"T5725","span":{"begin":247,"end":249},"obj":"Disease"},{"id":"T5726","span":{"begin":282,"end":284},"obj":"Disease"},{"id":"T5727","span":{"begin":322,"end":324},"obj":"Disease"},{"id":"T80900","span":{"begin":201,"end":204},"obj":"Disease"},{"id":"T5687","span":{"begin":247,"end":249},"obj":"Disease"},{"id":"T5688","span":{"begin":282,"end":284},"obj":"Disease"},{"id":"T7031","span":{"begin":322,"end":324},"obj":"Disease"}],"attributes":[{"id":"A5724","pred":"mondo_id","subj":"T5724","obj":"http://purl.obolibrary.org/obo/MONDO_0004647"},{"id":"A5725","pred":"mondo_id","subj":"T5725","obj":"http://purl.obolibrary.org/obo/MONDO_0005301"},{"id":"A5726","pred":"mondo_id","subj":"T5726","obj":"http://purl.obolibrary.org/obo/MONDO_0005301"},{"id":"A5727","pred":"mondo_id","subj":"T5727","obj":"http://purl.obolibrary.org/obo/MONDO_0005301"},{"id":"A85832","pred":"mondo_id","subj":"T80900","obj":"http://purl.obolibrary.org/obo/MONDO_0004647"},{"id":"A47279","pred":"mondo_id","subj":"T5687","obj":"http://purl.obolibrary.org/obo/MONDO_0005301"},{"id":"A78992","pred":"mondo_id","subj":"T5688","obj":"http://purl.obolibrary.org/obo/MONDO_0005301"},{"id":"A84956","pred":"mondo_id","subj":"T7031","obj":"http://purl.obolibrary.org/obo/MONDO_0005301"}],"text":"To identify markers for early disease, autoantibody profiling was performed with a phage display technique, called serological antigen selection (SAS), on pooled CSF from Clinically Isolated Syndrome (CIS) patients (n = 4), who developed definite MS, early Relapsing Remitting (RR) MS (n = 6) and Primary Progressive (PP) MS (n = 6) patients."}